Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity with Better Effectiveness of Abatacept: Results from the Pan-European Registry Analysis

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1346-1352

  Gottenberg, J E ^a   Courvoisier, D S ^b   Hernandez, M V ^c   Iannone, F ^d   Lie, E ^e   Canhao H ^f   Pavelka, K ^g   Hetland, M L ^h   Turesson, C ^i,j   Mariette, X ^k   Finckh, A ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^e DIAKONHJEMMET HOSPITAL   (Norway)

^f UNIVERSITY OF LISBON   (Portugal)

^g INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ Rigshospitalet   (Denmark)

^j LUND UNIVERSITY   (Sweden)

^k UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; BLOOD; EUROPE; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; REGISTER; TREATMENT OUTCOME;

ABATACEPT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; REGISTRIES; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 84971299229     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39595     Document Type: Review

References (22)

1. Van Venrooij WJ, van Beers JJ, Pruijn GJ., Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011; 7: 391-8.
2. De Vries RR, Huizinga TW, Toes RE., Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun 2005; 25 Suppl: 21-5.
3. Snir O, Gomez-Cabrero D, Montes A., Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. Arthritis Res Ther 2014; 16: 414.
4. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC., Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R949-58.
5. Cohen S, Dougados M, Genovese MC, Burmester G, Greenwald M, Kvien T, et al., Consistent inhibition of structural damage progression by rituximab in medically important subgroups of patients with an inadequate response to TNF inhibitors: week 56 REFLEX results [abstract]. Arthritis Rheum 2007; 66 Suppl:S152.
6. Isaacs JD, Olech E, Tak PP, Deodhar A, Keystone E, Emery P, et al., Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients [abstract]. Ann Rheum Dis 2009; 68 Suppl 2:442.
7. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, et al., B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63: 933-8.
8. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al., Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-80.
9. De Keyser F, Hoffman I, Durez P, Westhovens R, MIRA Study Group. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis Registry. J Rheumatol 2014; 41: 1761-5.
10. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al., Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the Orencia and Rheumatoid Arthritis registry. Ann Rheum Dis 2012; 71: 1815-9.
11. Nusslein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al., Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 2015; 16: 176.
12. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al., A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.
13. Hetland ML., DANBIO: powerful research database and electronic patient record. Rheumatology (Oxford) 2011; 50: 69-77.
14. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
15. Kristensen LE, Saxne T, Geborek P., The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600-6.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. Little RJ, Rubin DB., Statistical analysis with missing data. 2nd ed. New York: Wiley & Sons; 2002.
18. Lv Q, Yin Y, Li X, Shan G, Wu X, Liang D, et al., The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One 2014; 9: e89442.
19. Pieper J, Herrath J, Raghavan S, Muhammad K, van Vollenhoven R, Malmstrom V, et al., CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34.
20. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al., Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68: 1220-7.
21. Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al., Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014; 41: 666-72.
22. Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, et al., Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185: 1558-67.